Impact of pegaspargase dose capping on incidence of pegaspargase-related adverse events in adults.
Emily TiaoCiera L BernhardiJames A TrovatoJustin LawsonHyunuk SeungAshkan EmadiAlison P DuffyPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
The incidence of serious clinical toxicities was low in this study, particularly pegaspargase-related venous thromboembolism. This suggests that the practice of capping pegaspargase doses at 3750 units, coupled with vigilant monitoring and prophylaxis for pegaspargase-related adverse events, can allow for the inclusion of this drug in the treatment of older individuals.